Expression of miR-204 and Consequences on Capillarization in Limb Muscles of Patients With COPD

NCT02903043 | Unknown

• 1 other identifier: MIR-20895
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Limb muscle dysfunction, characterized by loss of capillaries, is amongst the most troublesome systemic consequences of chronic obstructive pulmonary disease (COPD) leading to poor functional status and premature mortality. One prevailing hypothesis stipulates that modification in the expression of miR-204 leads to change the regulation of angiogenesis in vastus lateralis of patients with COPD when compared to controls.

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

MicroRNAs; Angiogenesis; Skeletal muscle; COPD

Outcome Measures

Primary Outcomes (1)

• miR-204 in limb muscles in patients with COPD

  i)To measure miR-204 level in the quadriceps of patients with COPD in comparison to controls. ii) To study possible involvement of miR-204 on pathways regulating angiogenesis and on muscle microcirculation in these individuals.

  At baseline (COPD patients in a stable state of the disease)

Secondary Outcomes (1)

• microRNAs in limb muscles of patients with COPD

  At baseline (COPD patients in a stable state of the disease)

Study Arms (2)

COPD patients

Quadriceps biopsies will be done. No drug administration.

Healthy controls

Quadriceps biopsies will be done. No drug administration.

Eligibility Criteria

• Age: 50 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with COPD

You may qualify if:

• COPD (FEV1/FVC \< 0.70)
• Healthy subjects: no evidence of airways obstruction (FEV1/FVC \> 0.70 and FEV1 \> 0.80 predicted)
• Smoking history \> 10 pack-years
• Ex-smoker \>6 months

You may not qualify if:

• Chronic hypoxemia and/or hypercapnia (PaO2 \< 60 mmHg or SpO2 \< 88% at rest and/or PaCO2 \> 45 mmHg)
• Recent exacerbation or oral corticosteroids (\< 2 months)
• Recent cancer (\< 3 years)
• Diabetes
• Myopathy, neuromuscular, neurological or articular diseases
• Kidney disease
• Other respiratory diseases
• Unstable cardiac disease
• Physical activity score \> 9 in the Voorips questionnaire
• BMI \> 30

Sponsors & Collaborators

• Laval University: lead
• Canadian Institutes of Health Research (CIHR): collaborator

Study Sites (1)

Institut universitaire de cardiologie et de pneumologie de Québec

Québec, G1V 4G5, Canada

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood sample ad muscle biopsy of vastus lateralis (quadriceps)

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• François Maltais, MD

  Laval University

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Ph.D.

Study Record Dates

• First Submitted: April 9, 2015
• First Posted: September 16, 2016
• Study Start: February 1, 2013
• Primary Completion: April 1, 2015
• Study Completion: February 1, 2018
• Last Updated: May 10, 2017

Record last verified: 2017-05

Locations

CA (1)